Humana (HUM)
266.68
+0.00 (0.00%)
NYSE · Last Trade: Aug 11th, 4:50 AM EDT
Detailed Quote
| Previous Close | 266.68 |
|---|---|
| Open | - |
| Bid | 266.75 |
| Ask | 274.00 |
| Day's Range | N/A - N/A |
| 52 Week Range | 206.87 - 382.72 |
| Volume | 0 |
| Market Cap | 34.27B |
| PE Ratio (TTM) | 20.44 |
| EPS (TTM) | 13.1 |
| Dividend & Yield | 3.540 (1.33%) |
| 1 Month Average Volume | 1,983,765 |
Chart
About Humana (HUM)
Humana is a leading health insurance company that provides a wide range of health and wellness solutions to individuals, families, and employers. The organization offers Medicare Advantage plans, Medicaid services, and individual health insurance policies, focusing on enhancing the health and well-being of its members. Additionally, Humana invests in technology and innovative care management services, aiming to improve healthcare delivery and patient outcomes. The company is dedicated to integrating medical and wellness services to create a comprehensive approach to health management for its customers. Read More
News & Press Releases
Shares of behavioral health company LifeStance Health (NASDAQ:LFST)
jumped 11% in the afternoon session after the company reported mixed second-quarter 2025 results, delivering an earnings beat and a full-year profit forecast that topped Wall Street estimates. The mental healthcare provider's revenue for the quarter grew 10.6% year-over-year to $345.3 million, which was in line with analyst forecasts, driven by a 10.7% increase in sales volumes. On the bottom line, the company demonstrated improved profitability, posting a GAAP loss of $0.01 per share. This marked a significant improvement from the $0.06 per-share loss in the same period last year and beat consensus estimates for a $0.03 loss. Looking ahead, management provided a full-year Adjusted EBITDA forecast with a midpoint of $145 million, above analyst expectations. However, the company's revenue guidance for the next quarter came in below estimates, creating a mixed picture for investors.
Via StockStory · August 8, 2025
Shares of healthcare services company Astrana Health
jumped 34.2% in the morning session after the company reported better-than-expected second-quarter sales and significantly raised its full-year revenue forecast, overshadowing a miss on earnings per share. The healthcare services company announced second-quarter revenue of $654.8 million, a 34.7% increase year-over-year. While this topped sales expectations, its GAAP profit of $0.19 per share fell short of analysts' consensus estimates. However, investors focused on the company's strong future outlook. Astrana boosted its full-year revenue guidance to a midpoint of $3.2 billion, a significant jump from the previous $2.6 billion forecast. Furthermore, its third-quarter revenue projection of $945 million is 17.2% above what analysts were anticipating.
Via StockStory · August 8, 2025
Humana Stock Gains On Upbeat Earnings And Raised Guidance, Drawing Retail Praise And UnitedHealth Contrastsstocktwits.com
Via Stocktwits · July 30, 2025
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
fell 29.8% in the afternoon session after the company reported disappointing second-quarter financial results and slashed its full-year forecast. The radiopharmaceutical company announced quarterly revenue of $378 million and adjusted earnings per share of $1.57, both of which missed analysts' expectations. A key factor in the performance was an 8.3% decrease in sales for its main product, PYLARIFY, which faced increased competition. Compounding the issue, Lantheus lowered its full-year guidance significantly. The company projected full-year revenue between $1.47 billion and $1.51 billion, well below the consensus estimate of $1.57 billion. Similarly, its earnings per share forecast of $5.50 to $5.70 fell far short of the anticipated $6.64.
Via StockStory · August 6, 2025
Palantir, Pfizer, Hims & Hers, Intel, UnitedHealth: Stocks Making The Biggest Moves Todaystocktwits.com
Via Stocktwits · August 5, 2025
Bragar Eagel & Squire, P.C. Litigation Attorney Brandon Walker Encourages Investors Who Suffered Losses In Humana (HUM) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · July 31, 2025
The firm now expects full-year adjusted earnings per share of $6.30 to $6.40, up from its previous guidance of $6.00 to $6.20.
Via Stocktwits · July 31, 2025
Let's delve into the developments on the US markets one hour before the close of the markets on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Via Chartmill · July 30, 2025
Shares of health insurance company Humana (NYSE:HUM)
jumped 4.9% in the morning session after the company reported better-than-expected second-quarter results and raised its full-year financial guidance. The health insurer lifted its forecast for full-year adjusted earnings to approximately $17 per share, up from a prior estimate of about $16.25 and surpassing analysts' projections. Humana also increased its annual revenue guidance to at least $128 billion. Adding to the positive news, the company signaled that its decline in Medicare Advantage membership would be less severe than previously feared, forecasting a loss of up to 500,000 members instead of 550,000. This strong report and optimistic outlook provided a notable contrast to the more disappointing guidance recently issued by some of its peers in the health insurance sector, boosting investor confidence.
Via StockStory · July 30, 2025
Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN)
jumped 3.1% in the morning session after Cantor Fitzgerald upgraded the stock to Overweight from Neutral and raised its price target to $42 from $36. The upgrade followed positive developments in the company's planned acquisition of Sage Therapeutics. Supernus announced that the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act for the deal had expired. The expiration of this period, a requirement for major mergers and acquisitions in the U.S., removed a key regulatory hurdle, allowing the transaction to proceed. The tender offer for Sage shares was set to expire on July 30, 2025, after which Supernus planned to complete the merger. This acquisition was expected to enhance Supernus's product portfolio with Sage's innovative treatments, a move that likely bolstered analyst confidence.
Via StockStory · July 30, 2025
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.
Via Chartmill · July 30, 2025
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · July 30, 2025
Humana beat Q2 EPS and revenue estimates and raised its 2025 outlook, driven by strong PDP growth and higher CenterWell patient volumes.
Via Benzinga · July 30, 2025
GSK now expects turnover growth to be toward the top end of 3% to 5% and core earnings per share growth to be closer to 8% at constant exchange rate.
Via Stocktwits · July 30, 2025
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Via Chartmill · July 30, 2025
Health insurance company Humana (NYSE:HUM) announced better-than-expected revenue in Q2 CY2025, with sales up 9.6% year on year to $32.39 billion. The company’s full-year revenue guidance of $128 billion at the midpoint came in 1% above analysts’ estimates. Its GAAP profit of $4.51 per share was 24% below analysts’ consensus estimates.
Via StockStory · July 30, 2025
Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share (EPS) for the quarter ended June 30, 2025 (2Q25) versus the quarter ended June 30, 2024 (2Q24) and for the six months ended June 30, 2025 (YTD 2025) versus the six months ended June 30, 2024 (YTD 2024) as noted in the tables below.
By Humana Inc. · Via Business Wire · July 30, 2025
Investors may also keep an eye on any developments on the trade news front as President Donald Trump’s Aug. 1 tariff deadline draws closer.
Via Stocktwits · July 30, 2025
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO)
fell 20.2% in the morning session after the company reported second-quarter results that included a significant cut to its full-year financial guidance, sparking a selloff.
Via StockStory · July 29, 2025
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN)
jumped 7.8% in the morning session after the company reported strong second-quarter 2025 financial results and raised its full-year guidance. The life sciences company announced that its revenue climbed 15% year-over-year to $182 million, driven by growth across all its franchises and geographies. Profitability also saw a substantial increase, with net income rising to $14.87 million from $5.71 million in the same quarter last year. A key indicator of future performance, company orders, grew by over 20%. Buoyed by these strong results, Repligen lifted its full-year 2025 revenue forecast to a range of $715 million to $735 million.
Via StockStory · July 29, 2025
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN)
fell 3.8% in the afternoon session after weakness in the healthcare sector became pronounced following a poor sales report from a key competitor. The negative sentiment was partly fueled by health insurance giant UnitedHealth Group, which reported a miss on its second-quarter earnings and issued a profit warning, casting a pall over the entire sector. More directly, NeoGenomics, a company also operating in the cancer diagnostics space, reported that it had missed its second-quarter sales targets. This news, which sent NeoGenomics' stock down significantly, suggested a potentially more challenging market environment for companies involved in oncology diagnostics, a core business for Myriad Genetics.
Via StockStory · July 29, 2025
Health insurance company Humana (NYSE:HUM)
will be announcing earnings results this Wednesday morning. Here’s what you need to know.
Via StockStory · July 28, 2025